Crossmark

Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c

Crossref DOI link: https://doi.org/10.1038/nbt.3801

Published Online: 2017-02-06

Published Print: 2017-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pan, Bifeng https://orcid.org/0000-0001-9746-3420
Askew, Charles https://orcid.org/0000-0002-6131-6602
Galvin, Alice

Heman-Ackah, Selena

Asai, Yukako

Indzhykulian, Artur A

Jodelka, Francine M

Hastings, Michelle L

Lentz, Jennifer J

Vandenberghe, Luk H https://orcid.org/0000-0002-3508-4924
Holt, Jeffrey R

Géléoc, Gwenaëlle S
License Information

Text and Data Mining valid from 2017-02-06
More Information

Article History

Received: 27 May 2016

Accepted: 23 January 2017

First Online: 6 February 2017

Competing interests

: A patent #00633-0203P01 on “Materials and methods for delivering nucleic acids to cochlear and vestibular cells” has been deposited by L.H.V., G.S.G. and J.R.H. The Anc80L65 vector is patented by L.H.V., patent #WO/2015/054653 – “Methods of predicting ancestral virus sequence and uses thereof.” L.H.V. is co-founder and SAB member of GenSight Biologics and consultant to various gene therapy companies. L.H.V. receives research support from Selecta Biosciences and Lonza Houston on Anc-AAV development and discovery.